ILX 295501

Drug Profile

ILX 295501

Alternative Names: LY 295501

Latest Information Update: 11 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Genzyme Oncology
  • Class Antineoplastics; Small molecules; Sulfonylureas
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer

Most Recent Events

  • 29 Dec 2004 ILEX Oncology has been acquired by Genzyme Corporation
  • 27 May 2004 A clinical study has been added to the pharmacokinetics section
  • 20 Oct 2000 Phase-II clinical trials for Malignant melanoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top